WO2009108235A3 - Compositions and methods for modulating immune responses to nucleic acids - Google Patents

Compositions and methods for modulating immune responses to nucleic acids Download PDF

Info

Publication number
WO2009108235A3
WO2009108235A3 PCT/US2008/085571 US2008085571W WO2009108235A3 WO 2009108235 A3 WO2009108235 A3 WO 2009108235A3 US 2008085571 W US2008085571 W US 2008085571W WO 2009108235 A3 WO2009108235 A3 WO 2009108235A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
nucleic acids
immune responses
modulating immune
Prior art date
Application number
PCT/US2008/085571
Other languages
French (fr)
Other versions
WO2009108235A2 (en
Inventor
Ying K. Tam
Susan D. De Jong
Kaley D. Wilson
Original Assignee
Tekmira Pharmaceuticals Corporation
University Of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tekmira Pharmaceuticals Corporation, University Of British Columbia filed Critical Tekmira Pharmaceuticals Corporation
Publication of WO2009108235A2 publication Critical patent/WO2009108235A2/en
Publication of WO2009108235A3 publication Critical patent/WO2009108235A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to methods and compositions for modulating an immune response generated by a subject in response to the administration of a nucleic acid. The invention includes methods and compositions for enhancing an immune response generated by the administration of an immunostimulatory oligonucleotide by coadministration of a lipid particle, as well as methods of reducing an immune response generated by the administration of a nucleic acid by coadministration of an inhibitor of a src family kinase.
PCT/US2008/085571 2007-12-07 2008-12-04 Compositions and methods for modulating immune responses to nucleic acids WO2009108235A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US568307P 2007-12-07 2007-12-07
US61/005,683 2007-12-07

Publications (2)

Publication Number Publication Date
WO2009108235A2 WO2009108235A2 (en) 2009-09-03
WO2009108235A3 true WO2009108235A3 (en) 2010-01-14

Family

ID=41016640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/085571 WO2009108235A2 (en) 2007-12-07 2008-12-04 Compositions and methods for modulating immune responses to nucleic acids

Country Status (1)

Country Link
WO (1) WO2009108235A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5809756B2 (en) 2011-10-20 2015-11-11 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． Light source with quantum dots

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20070212328A1 (en) * 2003-10-13 2007-09-13 Bruck Claudine E M Immunogenic Compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20070212328A1 (en) * 2003-10-13 2007-09-13 Bruck Claudine E M Immunogenic Compositions

Also Published As

Publication number Publication date
WO2009108235A2 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
JO2761B1 (en) 1Phenyl-2-Pyridinyl Alkyl Alcohol Derivatives As Phosphodiesterase Inhibitors
NZ600725A (en) Methods and compositions for delivery of nucleic acids
WO2009018909A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2007092792A3 (en) Yeast-based vaccine for inducing an immune response
WO2008116078A3 (en) Stimulation of an immune response by cationic lipids
EP3156069B8 (en) Compositions, methods, and kits for eliciting an immune response
WO2010031825A3 (en) Methods and compositions for the treatment of cancer
CA2818187C (en) Bromodomain inhibitors and uses thereof
CA2871471C (en) Dna-pk inhibitors
WO2007109812A3 (en) Immunopotentiating compounds
WO2011005799A3 (en) Rna containing modified nucleotides and use thereof in vaccines
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2010013224A3 (en) Curcumin nanoparticles and methods of producing the same
WO2013057013A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
WO2010088368A3 (en) Imidazopyrazines as protein kinase inhibitors
MY161461A (en) Akt and p70 s6 kinase inhibitors
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2011056511A3 (en) 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
WO2009055076A3 (en) Methods and compositions for inhibition of immune responses and autoimmunity
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
WO2010040843A3 (en) Dibenzocycloheptanone derivatives and pharmaceutical agents containing said compounds
MX356126B (en) Use of glutamide stabilizers.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08872950

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08872950

Country of ref document: EP

Kind code of ref document: A2